This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center
Key Sessions
Kyle Schneider, PhD
Personalized Medicine for Agriculture – How Natural and Designed Macromolecules Are Reshaping Crop Protection and How We Grow Food
Vestaron
Meg Brousseau, Ph.D.
Tackling ASCVD at Scale Via a Suite of Long-acting Oligonucleotide Therapies
Novartis
Frank Bennett, PhD
Antisense Based Therapy for Neurological Diseases
Ionis Pharmaceuticals
Sarah DeVos, PhD
Targeting Transferrin Receptor to Enable Uniform Biodistribution of Antisense Oligonucleotides Using a Systemic Dose Route
Denali Therapeutics
George Church, PhD
Machine Learning + Multiplex Libraries
Harvard Medical School
Jacob Hyllested-Winge, M.D.
Development and Approval of RIVFLOZA® (Nedosiran)
Novo Nordisk